11β-hydroxylase deficiency epidemiology and demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons. 11β-hydroxylase deficiency accounts for 5 percent of all cases of congenital adrenal hyperplasia and it is considered the second most frequent variant after 21-hydroxylase deficiency. The incidence of 11β-hydroxylase deficiency is 1 per 100,000 persons. Also, this disease is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns. 11β-hydroxylase deficiency affects males and females equally.
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons.
Incidence
- 11β-hydroxylase deficiency accounts for 5 percent of all cases of congenital adrenal hyperplasia and it is considered the second most frequent variant after 21-hydroxylase deficiency.
- Worldwide, the incidence of 11β-hydroxylase deficiency is 1 per 100,000 persons.
- 11β-hydroxylase deficiency is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns.[1][2]
Gender
- 11β-hydroxylase deficiency affects males and females equally.
Race
- 11β-hydroxylase deficiency usually affects individuals of the Jewish race.
References
- ↑ Rösler A, Leiberman E, Cohen T (1992). “High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco”. Am J Med Genet. 42 (6): 827–34. doi:10.1002/ajmg.1320420617. PMID 1554023.
- ↑ White PC, Curnow KM, Pascoe L (1994). “Disorders of steroid 11 beta-hydroxylase isozymes”. Endocr. Rev. 15 (4): 421–38. doi:10.1210/edrv-15-4-421. PMID 7988480.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH